[{"id":"81289e73-f52b-4e02-9264-0ee67de30fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05585281","created_at":"2022-10-18T14:57:21.085Z","updated_at":"2024-07-02T16:35:41.618Z","phase":"Phase 2","brief_title":"A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy","source_id_and_acronym":"NCT05585281","lead_sponsor":"Yongpeng Wang","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiYi (fluzoparib) • Ankeda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 11/07/2025","primary_completion_date":" 11/07/2025","study_txt":" Completion: 12/22/2025","study_completion_date":" 12/22/2025","last_update_posted":"2023-07-28"},{"id":"dd542ef8-8a3e-4012-9da1-e863fc2acc9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05446883","created_at":"2022-07-07T16:57:05.494Z","updated_at":"2024-07-02T16:35:59.823Z","phase":"Phase 3","brief_title":"QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","source_id_and_acronym":"NCT05446883","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab) • Ankeda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 09/23/2022","start_date":" 09/23/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-11-30"},{"id":"dc1b1acf-7135-45a1-8a39-9849bf627339","acronym":"","url":"https://clinicaltrials.gov/study/NCT05398861","created_at":"2022-06-01T16:00:18.876Z","updated_at":"2024-07-02T16:36:09.637Z","phase":"Phase 2","brief_title":"Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer","source_id_and_acronym":"NCT05398861","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Ankeda (bevacizumab biosimilar) • utidelone IV (UTD1)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-06-01"},{"id":"a6258416-ff0f-41cb-98b2-0ef301eec3f3","acronym":"BEVTOR","url":"https://clinicaltrials.gov/study/NCT04527068","created_at":"2021-01-18T21:40:48.479Z","updated_at":"2024-07-02T16:36:40.921Z","phase":"Phase 2","brief_title":"QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04527068 - BEVTOR","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" RAS wild-type","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Ankeda (bevacizumab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/20/2020","start_date":" 09/20/2020","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2020-09-17"}]